U.S. Markets closed

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.04-0.48 (-2.23%)
At close: 4:00PM EDT
Sign in to post a message.
  • i
    itssofine2
    This needs to get back to $30 where it belongs. Im long here.
  • A
    Anonymous
    I've said this before and I'll say it again;
    There are NO therapies that improve LV EF and reduce events, in pill form, in the outpatient setting. The sickest gain the most; the lower the LV EF, the better the benefit. It would be asinine to ignore a safe oral outpatient inotrope that helps the sickest. Big pharma interested in a CHF portfolio; here's your chance.
  • Y
    Yahoo Finance Insights
    CYTK is up 9.60% to 22.38
  • R
    Randolph
    What's the lowdown on Cytokinetics these days. I see low trading volume and even lower today, and low blog volume. Sell if even now or dump if close to even, or HODL?
  • I
    Informed Observer
    Expect CYTK’s pre-offering weakness to be temporary and stock to resume upward trajectory upon completion of offering. The reasons are several: (i) $150MM share offering is small (9 percent of outstanding shares) and the private placement of $50MM of stock this week with health care specialist RTW Investments at $25.00 a share underscores CYTK’s value at prevailing levels….this independent assessment of fair value will be important to new institutional buyers and likely lead to a well oversubscribed offering, (ii) CYTK’s effective Investor Day presentation (yesterday) coupled with recent strategic announcements by RTW and Ji Xing better illuminate and corroborate the multiple indication, stacked investment opportunity associated with CK-274 and CYTK, and (iii) the Company’s strategic position as a leader in muscle function is now complimented by equivalent financial strength which will allow the Company to accelerate its therapeutics development agenda, both organically and perhaps by acquisition of complimentary small molecule therapies. The completion of this evening’s equity offering and recent strategic transactions will result in CYTK having $535M of cash (exclusive of amounts that might be received later upon completion of development and commercial milestones) against a pro forma share balance of ~67MM shares ($8.00 of cash per share) and an unlevered balance sheet with $50MM of debt. An positive read-out on August 7 on Galactic Phase 3 will also make CYTK that much more interesting as an acquisition target to a larger drug companies like Amgen that seek to grow their pipelines. The current consensus sell side analyst target of $36 appears conservative.
  • A
    Anonymous
    GALACTIC HF was a successful trial, and expecting a mortality benefit in this morbid population, was a pipe dream. This agent told the medical community that this agent was;
    1. An oral inotrope.
    2. A safe oral inotrope.
    3. A safe outpatient oral inotrope.
    4. A safe outpatient oral inotrope that reduced events.

    The need for additional therapeutic help for those folks with LVEF < 28% is dire. This is a welcome addition. It will be unfair if not approved. METEORIC will shed further light on this agents role in systolic dysfunction in terms of VO2 and functional capacity, and yes, this is an important agent to any big pharma interested in a strong CHF portfolio.

    And I haven’t even talked about their HOCM portfolio.
  • C
    CRAIG D
    CYTK is the one to own, partnership with AMGEN. Imo.
    AMGN could easily acquire CYTK to add to its Cardio programs.
    FYI ( bmy just announced acquiring myok)
    Bullish
  • A
    Anonymous
    SO unless there is something else: Met primary composite efficacy endpoint- statistically significant effect to reduce cardiovascular (CV) death or heart failure events BUT no reduction in the secondary endpoint of CV death . That implies a significant effect on heart failure events. That's about as much as anybody could hope for in a population with heart disease at high risk for MI, sudden death with a drug that's effective for heart failure. I bet most other secondary end points were met. and yes I did bet.
  • C
    CRAIG D
    obvious 'shortees' lost today on huge "breakout" move to New 52 week High on huge 6 million plus shares,most Bullish CYTK
    Congrats to CYTK team and AMGN
  • B
    Be More
    CYTK Notifications
    Oct 8, 2020
    Analyst Joseph Pantginis from H.C. Wainwright maintained a buy rating on Cytokinetics.
    StreetInsider>
    Oct 8, 2020
    Analyst Chad Messer from Needham downgraded their rating on Cytokinetics to buy.
    Markets>
    Oct 8, 2020
    Analyst Salim Syed from Mizuho Securities maintained a buy rating on Cytokinetics.
    Markets>
    Oct 5, 2020
    Analyst Edward Tenthoff from Piper Sandler reiterated a buy rating on Cytokinetics.
    TheFly>
    Oct 5, 2020
    Analyst Charles Duncan from Cantor Fitzgerald maintained a buy rating on Cytokinetics.
  • F
    Francesco
    Hi all, I was looking for some opinions on this board following the presentations at AHA last week. For the sake of clarity: I am long in Cytokinetics and at the moment it actually constitutes the biggest slice of my portfolio. Especially after what the Cytokinetics management team said in the Q3 earnings call, I did not find the detailed results of GALACTIC as encouraging as I was hoping (as I was expecting at least a subgroup of the study subjects to benefit from Omecamtiv also in terms of reduced mortality, besides the significant decrease in HF events). What do other long-term investors think?
  • A
    AlanE
    If MyoKardia jumped to $5B with the announcement of EXPLORER-HCM results and HFrEF is at least 2X the market of HCM, what happens when GALACTIC-HF results are announced?
  • g
    gregthewineguy
    Oral Presentation of data from Reldesemtiv SMA PII this Saturday. Stock likely up today on this announcement because it is an Oral Presentation at the Cure SMA Conference... usually theOral presentations are reserved for compelling stories at such conferences. We’ll see Saturday- I hope it’s good news for patients.
  • S
    Shripad
    This drug will emerge to be a competitor of Entresto. It has a potential to be the mainstay of heart failure treatment. It will swiftly be approved by FDA.
  • C
    CRAIG D
    Consolidation over, time to move to next level, news?
    Bullish
  • B
    Booda
    Is this interpretation of the result correct?

    The drug prevented the heart failure compared to placebo, but if the heart failure happened there was no difference between placebo and treatment in delaying/preventing cv death.
  • g
    gregthewineguy
    The results bode well not only for further development for SMA but for the ALS readout in Q4,- Robert Blum said at the annual meeting he expected that to be the most important readout of the year. Statistically significant dose dependent results with room to increase the dosage due to the safety profile of the drug are very promising.
  • S
    Shelly
    Quiet, before the next move higher imo

    FDA approval near?
    Bullish
  • A
    André
    Good news for CYTK and Reldesemtiv.
    hopefully a rise in the price next week.
    What do you think ?
  • j
    jm
    Analyst Actions:
    HC Wainwright Adjusts Cytokinetics PT to $43 From $59, Maintains Buy Rating
    Piper Sandler Adjusts Price Target on Cytokinetics to $25 From $36, Reiterates Overweight Rating

    Reason for the drop, second half of the last sentence:
    The companies said in a statement Thursday that while topline Phase III trial data showed the drug helped reduce the need for hospitalization and urgent treatments for heart failure patients with reduced ejection fraction, the drug did not appear to decrease the number of deaths from cardiovascular disease.
    Bullish